We have located links that may give you full text access.
Elucidating the Mechanisms of Sodium Benzoate in Alzheimer's Disease: Insights from Quantitative Proteomics Analysis of Serum Samples.
International Journal of Neuropsychopharmacology 2023 October 24
BACKGROUND: N-methyl-D-aspartate receptors (NMDARs) are crucial components of brain function involved in memory and neurotransmission. Sodium benzoate is a promising NMDAR enhancer and has been proven to be a novel, safe and efficient therapy for patients with Alzheimer's disease (AD). However, in addition to the role of sodium benzoate as an NMDA enhancer, other mechanisms of sodium benzoate in treating AD are still unclear. To elucidate the potential mechanisms of sodium benzoate in Alzheimer's disease, this study employed label-free quantitative proteomics to analyze serum samples from AD cohorts with and without sodium benzoate treatment.
METHODS: The serum proteins from each patient were separated into 24 fractions using an immobilized pH gradient, digested with trypsin and then subjected to nanoLC‒MS/MS to analyze the proteome of all patients. The nanoLC‒MS/MS data were obtained with a label-free quantitative proteomic approach. Proteins with fold changes were analyzed with STRING and Cytoscape to find key protein networks/processes and hub proteins.
RESULTS: Our analysis identified 861 and 927 protein groups in the benzoate-treatment cohort and the placebo cohort, respectively. The results demonstrated that sodium benzoate had the most significant effect on the complement and coagulation cascade pathways, amyloidosis disease, immune responses and lipid metabolic processes. Moreover, Transthyretin (TTR), Fibrinogen alpha chain (FGA), Haptoglobin (HP), Apolipoprotein B-100 (APOB), Fibrinogen beta chain (FGB), Apolipoprotein E (APOE) and Alpha-1-acid glycoprotein 1 (ORM1) were identified as hub proteins in the protein‒protein interaction networks.
CONCLUSIONS: These findings suggest that sodium benzoate may exert its influence on important pathways associated with AD, thus contributing to the improvement in the pathogenesis of the disease.
METHODS: The serum proteins from each patient were separated into 24 fractions using an immobilized pH gradient, digested with trypsin and then subjected to nanoLC‒MS/MS to analyze the proteome of all patients. The nanoLC‒MS/MS data were obtained with a label-free quantitative proteomic approach. Proteins with fold changes were analyzed with STRING and Cytoscape to find key protein networks/processes and hub proteins.
RESULTS: Our analysis identified 861 and 927 protein groups in the benzoate-treatment cohort and the placebo cohort, respectively. The results demonstrated that sodium benzoate had the most significant effect on the complement and coagulation cascade pathways, amyloidosis disease, immune responses and lipid metabolic processes. Moreover, Transthyretin (TTR), Fibrinogen alpha chain (FGA), Haptoglobin (HP), Apolipoprotein B-100 (APOB), Fibrinogen beta chain (FGB), Apolipoprotein E (APOE) and Alpha-1-acid glycoprotein 1 (ORM1) were identified as hub proteins in the protein‒protein interaction networks.
CONCLUSIONS: These findings suggest that sodium benzoate may exert its influence on important pathways associated with AD, thus contributing to the improvement in the pathogenesis of the disease.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app